Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

STENOCARE: New Product: More choice for treatment of Swedish patients with medical cannabis oil

Stenocare
Read the release

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER:  STENO

 

STENOCARE A/S ("STENOCARE") and Emerald Health Therapeutics Inc ("Emerald") hereby announces that the first product shipment and delivery of THC-CBD Balanced medical cannabis oil has been completed on February 12, 2021 to Sweden.
 

STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. In December 2020, the first THC oil products were delivered, and now the first THC-CBD oil products have been delivered to Sweden. With these two products available for treatment, there is more choice for doctors and patients when considering medical cannabis as a supplement to conventional treatment protocols.

In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor applied for a prescription for treatment with THC-CBD medical cannabis oil.

STENOCARE is a leading supplier of premium prescription-based medical cannabis products for patients' treatment to help them improve quality of life, and for Sweden their Canadian supplier of high-quality medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.

Niels V. Olsen, anesthesiologist, D.M.Sc., at "Smärt och Psykiatri Centrum Malmö" is commenting:

"We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis. We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries"

Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:

"With this second type of medical cannabis oil to Sweden there is more choice to doctors and patients. Now they both have a high-THC oil and a balanced THC-CBD oil product available for supplemental treatment"

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.